NIAID applauds the study sponsor, investigators, study staff, and—most importantly—the participants in South Africa and Uganda.

Wednesday, June 26, 2024 NIH Statement on Preliminary Efficacy Results of Twice-Yearly Lenacapavir for HIV Prevention in Cisgender Women Transmission electron micrograph of HIV-1 virus particles (colorized orange/yellow) replicating from an HIV-infected H9 T-cell (green). Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID NIAID applauds the top-line Phase 3 findings of twice-yearly lenacapavir for HIV pre-exposure prophylaxis among cisgender women, a population for whom biomedical HIV prevention evidence has been limited to date. The findings build on decades of discovery and translational research and collaboration between public and private sector to steer promising concepts from the laboratory to the clinic. The Institute looks forward to the release of additional data from this pivotal study, as well as the outcomes of companion studies of lenacapavir in other populations.  Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period. 

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107